Latest Headlines

Latest Headlines

WSJ: Pfizer animal health IPO could happen next month

Pfizer's animal health unit may be worth $20 billion, and that is the conundrum.

Mylan tries snatching Ranbaxy's rights to Novartis blockbuster

Generic drugmaker Mylan ($MYL), impatient that money is sitting on the table, has sued the FDA to try to snatch the rights to produce a generic of Novartis' ($NVS) blockbuster blood pressure med, Diovan.

Ranbaxy probes reactor in India as source of recall

Ranbaxy Laboratories is investigating whether splintered glass from the lining of a reactor at a plant in India is the source of particles found in the raw ingredients for generic Lipitor that were delivered to a Ranbaxy plant in the U.S. where the pills are finished.

U.S. patient sues Ranbaxy over generic Lipitor recall

Last month, Ranbaxy Laboratories recalled its version of the cholesterol-fighting pill Lipitor. By last week, the company had stopped making the drug, at least until it can iron out the manufacturing problems that caused fine glass particles to crop up in some pills. Along the way, the Indian company hasn't said much, at least not publicly--and that has inspired a New Jersey man to sue for information, not to mention a refund, Pharmalot reports.

Ranbaxy sued for handling of atorvastatin recall

Ranbaxy Laboratories' recall of generic Lipitor has spawned its first legal repercussion.

Ranbaxy's generic Lipitor recall may be tied to glass missing from shield

Ranbaxy Laboratories is trying to determine if a missing fragment of glass from a shield of a piece of machinery at a plant in India is the source of the problem that has caused it to halt production on its lucrative generic Lipitor product

Pfizer sharpens job-cutting ax for U.S. sales layoffs

Pfizer's U.S. sales reps are updating their résumés. The company's primary care sales force faces another round of job cuts, numbers as yet unspecified. The laid-off reps--to be notified Dec. 20, Dow Jones reports--will join thousands of previous patent-cliff casualties.

Dr. Reddy's discloses it recalled some generic Seroquel

The market has been focused this week on the recall of generic Lipitor by Ranbaxy Laboratories but it turns out there was another Indian generics company that recently retrieved a key generic drug.

Ranbaxy halts production of generic Lipitor; recall second in 3 months

The potential manufacturing glitches that Ranbaxy Laboratories has been having with generic Lipitor production are more complicated than initially suggested when the Indian generics maker ordered a recall last week because some pills may contain tiny glass particles. It turns out there was an earlier recall three months ago because of possible mispackaged pills that escaped broad public notice.

Ranbaxy recalls generic Lipitor from closely watched plant

The generic  Lipitor  that  Ranbaxy Laboratories  has recalled came out of an Indian plant that for the past 7 months has been under the watchful eye of a phalanx of independent consultants mandated under a 5-year consent decree made with federal authorities in the U.S.